Defining Impact of Early Life Epilepsy on Patient Outcomes

Neuroscience Research | June 18, 2019 | cookchildrens

It is well known that early-life epilepsies (ELEs) are associated with poor outcomes including intractable or drug-resistant seizures, developmental and cognitive disabilities, poor regulation of other functions controlled by the nervous system, as well as increased risk for mortality. Early-life epilepsies are defined by a diagnosis of epilepsy greater than 28 days of life and less than 3 years of age and are often divided into syndromic (identifiable features and/or characteristics such as genetic diseases, structural abnormalities, or metabolic diseases) versus nonsyndromic types.

Over the last several years, Cynthia Keator M.D. has led the efforts of Cook Children's Epilepsy Program and has been an active contributor to the Pediatric Epilepsy Research Consortium (PERC). As a participant in the multi-center early life epilepsy group, Cook Children's enrolled patients with new onset epilepsy (ages 28 days to 36 months); to identify variables which serve as predictors of outcome in ELEs. Their most recent article is a review of outcomes in ELE. Given that modern day medicine has allowed easier and better access to high quality imaging studies (MRI), more comprehensive genetic testings and newer medications, one might hypothesize that outcomes of ELE are improving. A total of 775 children were recruited from 17 centers and a total of 680 children met criteria for review in this study.

Many variables were identified including age at seizure onset, underlying etiology, seizure types and epilepsy type/syndrome, initial developmental status at the time of diagnosis/seizure onset, and mortality. The outcomes of these variables were then reviewed at follow up. Children included in the study had to have follow-up information for at least 6 months after the initial diagnosis of epilepsy. Some of the primary findings are summarized below.

Thirty-five percent of the patients developed drug resistance. Statistically significant factors that were identified to predict drug resistance were:

  • Development of epilepsy at < 1 year of age
  • Definitive developmental delay at the initial evaluation

The patients at lowest risk to develop intractability were those who:

  • Had normal development at diagnosis
  • Onset of epilepsy > 1 year of age

Factors predicting evolution from non-syndromic epilepsy to infantile spasms (15% of the patients):

  • Developmental delay at initial diagnosis
  • Development of epilepsy very early (i.e. 0-2 months)

Factors predicting development of new seizure types after initial presentation with infantile spasms (23% of the patients):

  • Developmental delay at initial diagnosis

Factors associated with developmental delay after initial diagnosis (23% of the patients)

  • Onset of epilepsy in infancy
  • Identified etiology
  • Initial epilepsy type
  • Development of drug resistance in infancy (but not > 1 year)

Death occurred in 22 patients (2.9%) of the cohort. No deaths occurred in patients with unknown etiology and who were developing normally at the time of initial evaluation. Specific causes of death were not available.

This current data suggests that even with advances in medicine and technology there is continued poor outcome for ELEs. This article also demonstrates that development of epilepsy within the first year of life (regardless of etiology) should always be viewed with utmost urgency and importance until proven otherwise. Most importantly this data emphasizes the ongoing need to develop evidenced based standard care for ELEs with the goal to optimize early outcomes.

This article is available for free download from Epilepsy and Behavior until 7/27/2019 by clicking here.

Contributing author

Headshot of Cynthia Keator

Cynthia Keator, MD


Card Link

You Might Also Like



Jane and John Justin Neurosciences Center Welcomes Four New Faculty Members

The Jane and John Justin Neurosciences Center is growing to meet the needs of our region. According to the U.S. Census Bureau, Dallas (#3) and Fort Worth (#4) are among a total of five Texas cities listed in the 15 fastest growing large cities and both are listed within the top 15 most populous cities in the country. 

Photo of Lindsey Carnes, Ph.D., neuropsychology faculty member


Cook Children’s Neurosciences welcomes new Neuropsychology faculty member

The Jane and John Justin Neurosciences Center at Cook Children’s continues to grow our faculty to meet the needs of our patients. In January 2022, we welcomed Lindsey Carnes, Ph.D. as our fourth neuropsychologist.



Texas Pediatric Neuroscience Network Conference March 6-8, 2020

The second annual Texas Pediatric Neuroscience Network Conference will be held March 6-8 at the Driskill Hotel in Austin, Texas.